Orthospace obtains CE Mark for shoulder balloon implant
The InSpace balloon is for treatment of shoulder Rotator-Cuff injury.
OrthoSpace has developed an implantable, biodegradable balloons for orthopedic procedures. The CE Mark is for the company's first product, the InSpace balloon, for treatment of shoulder Rotator-Cuff injury. The Rotator-Cuff is a complex network of muscles and tendons that hold the shoulder in place and enable the arm to rotate. The InSpace balloon, is designed to replicate the action of the bursa - a fluid sac between the Rotator-Cuff and the upper bone of the shoulder - during the healing process. It removes friction, and correctly spaces the tendons and muscles in the Rotator-Cuff.
OrthoSpace estimates the European market for treatment of shoulder Rotator-Cuff injury at hundreds of millions of dollars a year.
The implantable balloons were originally developed by BioProtect to separate healthy tissue from tumors, in order to protect healthy tissue during radiation therapy.
OrthoSpace also appointed Itay Barnea as CEO. He has experience in medical devices and regulations, and previously worked for Johnson & Johnson. He replaces Shaul Shochat, who simultaneously served as CEO of BioProtect. Shochat will continue at that job.
Xenia owns 18% of OrthoSpace.
Published by Globes [online], Israel business news - www.globes-online.com - on August 2, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options